Rating
Innovation
Pricing
Technology
Usability
We have discovered similar tools to what you are looking for. Check out our suggestions for similar AI tools.
2025-10-17
OpenAI suspends Sora depictions of Martin Luther King Jr. following a request from his family
OpenAI has paused video generations of Martin Luther King Jr. on Sora at the request of King Inc., the estate that manages his legacy. The company said in an announcement on X that it worked with the [...]
2025-05-30
How Ozempic maker Novo Nordisk fell behind Eli Lilly in the weight loss drug race
Novo Nordisk (NVO) makes Ozempic, the best-known GLP-1 drug out today. And until quite recently, the Danish pharma giant consistently led the pack in new prescriptions, becoming virtually synonymous w [...]
2025-03-21
The Morning After: A closer look at Facebook’s leadership
For all of the money and clout Meta has, it can’t stop the triennial emergence of a whistleblower revealing how awful its leadership is. Careless People, the tell-all memoir from former staffer Sara [...]
2025-02-24
Xbox showcase gave release dates for three indie games we're looking forward to
Monday's ID@Xbox indie showcase included release dates for a few upcoming games we've been tracking. 33 Immortals, which lets you round up 32 pals to try to escape hell with, arrives next mo [...]
2025-03-07
Wegovy's price cut, Amgen's Ozempic competitor, and Big Pharma's tax cut: Pharma news roundup
Novo Nordisk just cut the price of its weight-loss drug, Wegovy, by more than half for patients who pay without insurance. Amgen (AMGN) announced this week that it has begun two late-stage clinical tr [...]
2025-04-01
Here's how much Ozempic and similar drugs have soared in popularity since 2018
The use of GLP-1 meds — made popular by Ozempic (NVO) — among U.S. adults without diabetes more than tripled between 2018 and 2022, with annual spending surging from $1.6 billion to $5.8 billion.R [...]
2025-05-16
Novo Nordisk's CEO is out after the Ozempic maker's stock dropped 50% in a year
Novo Nordisk (NVO) CEO Lars Fruergaard Jørgensen will step down after eight years at the helm of the Danish pharmaceutical giant responsible for the blockbuster drugs Ozempic and Wegovy, the company [...]